Is NVO or SCLX more undervalued in 2026?

CirclFi compares Novo Nordisk A/S (NVO) and Scilex Holding Company (SCLX) using 13 institutional-grade valuation models. NVO has a Quality of Company score of 10.0/10 while SCLX scores 4.7/10.

Which is a better buy — NVO or SCLX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NVO and SCLX valuations compare?

NVO at $45.51 and SCLX at $7.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NVO vs SCLX Valuation Comparison 2026 — Intrinsic Value Analysis

NVO

Drug Manufacturers - General

Novo Nordisk A/S

Quality

10.0

out of 10

Value Trap

SAFE

Price

$45.51

Last close

Models

12/13

Active

SCLX

Drug Manufacturers - General

Scilex Holding Company

Quality

4.7

out of 10

Value Trap

WARN

Price

$7.21

Last close

Models

5/13

Active

Model-by-Model Comparison

Model	Type	NVO Fair Value	NVO Upside	SCLX Fair Value	SCLX Upside
Bayesian DCF	Intrinsic	$31.50	-30.8%	$33.36	+463.5%
Earnings Power Value	Intrinsic	$44.05	-3.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$26.84	-41.0%	$13.06	+81.2%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVO vs SCLX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVO vs SCLX — Which Stock Is More Undervalued?

NVO scores higher with a 10.0/10 quality rating vs SCLX's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Novo Nordisk A/S (NVO) and Scilex Holding Company (SCLX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVO currently trades at $45.51 with a QOC of 10.0/10, while SCLX trades at $7.21 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).